Importance Multiple myeloma is a hematologic malignancy characterized by presence of
abnormal clonal plasma cells in the bone marrow, with potential for uncontrolled growth …

Cardiovascular Toxic Effects of Targeted Cancer Therapies | New England Journal of Medicine
Skip to main content Access provided byUT MD ANDERSON CANCER CENTER The New …

Background Lenalidomide plus dexamethasone is a standard treatment for patients with
newly diagnosed multiple myeloma who are ineligible for autologous stem-cell …

Background Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell
therapy has been shown to have activity in patients with relapsed or refractory multiple …

PURPOSE A combination of anti–B-cell maturation antigen (BCMA) and anti-CD19 chimeric
antigen receptor (CAR) T cells induced high response rates in patients with relapsed or …

PURPOSE G protein–coupled receptor, class C group 5 member D (GPRC5D) is considered
to be a promising surface target for multiple myeloma (MM) immunotherapy. Here, we report …

We conducted a pooled analysis of 869 individual newly diagnosed elderly patient data from
3 prospective trials. At diagnosis, a geriatric assessment had been performed. An additive …

Purpose The aim of the International Myeloma Working Group was to develop practical
recommendations for the diagnosis and management of multiple myeloma–related renal …

Background Panobinostat is a potent oral pan-deacetylase inhibitor that in preclinical
studies has synergistic anti-myeloma activity when combined with bortezomib and …

Despite enormous advances, management of multiple myeloma (MM) remains challenging.
Multiple factors impact the decision to treat or which regimen to use at MM …